The Director General of the Agence nationale de sécurité du médicament et des produits de santé will make a decision within two hundred and ten days of the submission of a complete application file.
When the Director General of the Agency makes use of the option granted to him under 5° of Article R. 5121-34, these time limits are suspended until the additional information required has been provided.
The Director General of the Agency draws up an assessment report on the medicinal product including comments relating to the chemical, pharmaceutical and biological data, pre-clinical trials and biomedical research, as well as the risk management and pharmacovigilance system set up for the medicinal product or product concerned. The assessment report is updated by the Director General of the Agency as soon as new information becomes available which is important for the evaluation of the quality, safety and efficacy of the medicinal product concerned.